Search research articles
Contact Us
Filters
Showing results (661-670 of 869) with videos related to
Page
of 87
Sort By:
Cancer Cell
|
April 18, 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
Daniel R Carrasco, Giovanni Tonon, Yongsheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2013
AACR Cancer Progress Report 2013
, Charles L Sawyers, Cory Abate-Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia
Irene M Ghobrial, Aldo Roccaro, Fangxin Hong, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Nature Communications
|
January 6, 2016
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival
Hiroto Ohguchi, Teru Hideshima, Manoj K Bhasin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Leukemia
|
May 12, 2018
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
Mehmet Kemal Samur, Stephane Minvielle, Annamaria Gulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Blood
|
January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo, Teru Hideshima, Andrew L Kung, et al.
Cancer Research
|
August 8, 2015
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma
Jian-Jun Zhao, Zhang-Bo Chu, Yu Hu, et al.
Page
of 87
Search research articles
Search
Showing results (661-670 of 869) with videos related to
Sort By:
Page
of 87
Cancer Cell
|
April 18, 2006
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
Daniel R Carrasco, Giovanni Tonon, Yongsheng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2013
AACR Cancer Progress Report 2013
, Charles L Sawyers, Cory Abate-Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia
Irene M Ghobrial, Aldo Roccaro, Fangxin Hong, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
November 1, 2022
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, et al.
Nature Communications
|
January 6, 2016
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival
Hiroto Ohguchi, Teru Hideshima, Manoj K Bhasin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 26, 2017
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L McCarthy, Sarah A Holstein, Maria Teresa Petrucci, et al.
Leukemia
|
May 12, 2018
Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
Mehmet Kemal Samur, Stephane Minvielle, Annamaria Gulla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
Irene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Blood
|
January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo, Teru Hideshima, Andrew L Kung, et al.
Cancer Research
|
August 8, 2015
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma
Jian-Jun Zhao, Zhang-Bo Chu, Yu Hu, et al.
Page
of 87